Wall Street brokerages expect Quidel Co. (NASDAQ:QDEL) to post sales of $115.02 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Quidel’s earnings, with the lowest sales estimate coming in at $110.75 million and the highest estimate coming in at $122.15 million. Quidel reported sales of $52.81 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 117.8%. The company is expected to announce its next quarterly earnings report on Wednesday, February 14th.

On average, analysts expect that Quidel will report full-year sales of $115.02 million for the current financial year, with estimates ranging from $273.60 million to $285.91 million. For the next financial year, analysts anticipate that the company will post sales of $489.01 million per share, with estimates ranging from $485.10 million to $491.30 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that cover Quidel.

Quidel (NASDAQ:QDEL) last released its quarterly earnings data on Wednesday, November 1st. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.21). Quidel had a negative net margin of 2.33% and a negative return on equity of 2.36%. The firm had revenue of $50.89 million during the quarter, compared to the consensus estimate of $50.47 million. During the same quarter last year, the business posted $0.10 earnings per share. Quidel’s revenue was up 3.1% compared to the same quarter last year.

A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of Quidel from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Canaccord Genuity restated a “buy” rating and issued a $52.00 price objective (up from $48.00) on shares of Quidel in a research report on Thursday, December 21st. CL King upgraded shares of Quidel from a “neutral” rating to a “buy” rating and set a $52.00 price objective for the company in a research report on Thursday, January 4th. Zacks Investment Research lowered shares of Quidel from a “hold” rating to a “strong sell” rating in a research report on Thursday, December 28th. Finally, Barclays raised their price objective on shares of Quidel from $45.00 to $49.00 and gave the company an “overweight” rating in a research report on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $50.00.

Quidel (NASDAQ:QDEL) opened at $45.99 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 6.28 and a quick ratio of 5.68. Quidel has a 1 year low of $18.25 and a 1 year high of $47.60. The company has a market cap of $1,560.00, a P/E ratio of -287.44, a PEG ratio of 1.48 and a beta of 1.15.

In related news, CEO Douglas C. Bryant sold 12,000 shares of the firm’s stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $41.15, for a total value of $493,800.00. Following the sale, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at $12,200,686.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Ratan S. Borkar sold 7,965 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $38.91, for a total transaction of $309,918.15. Following the completion of the sale, the senior vice president now directly owns 11,084 shares in the company, valued at $431,278.44. The disclosure for this sale can be found here. Insiders sold 385,790 shares of company stock worth $15,760,155 over the last ninety days. 22.00% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the business. Acrospire Investment Management LLC raised its stake in shares of Quidel by 42.2% during the second quarter. Acrospire Investment Management LLC now owns 3,678 shares of the company’s stock worth $100,000 after acquiring an additional 1,091 shares in the last quarter. Legal & General Group Plc raised its stake in shares of Quidel by 4.0% during the second quarter. Legal & General Group Plc now owns 7,209 shares of the company’s stock worth $197,000 after acquiring an additional 278 shares in the last quarter. Great West Life Assurance Co. Can raised its stake in shares of Quidel by 162.7% during the third quarter. Great West Life Assurance Co. Can now owns 4,642 shares of the company’s stock worth $204,000 after acquiring an additional 2,875 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Quidel during the third quarter worth approximately $205,000. Finally, Russell Investments Group Ltd. purchased a new position in shares of Quidel during the second quarter worth approximately $209,000. 92.71% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/16/115-02-million-in-sales-expected-for-quidel-co-qdel-this-quarter.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Get a free copy of the Zacks research report on Quidel (QDEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.